Northern Trust Corp Has $164,000 Stock Position in Coya Therapeutics, Inc. (NASDAQ:COYA)

Northern Trust Corp boosted its position in Coya Therapeutics, Inc. (NASDAQ:COYA) by 12.2% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 28,549 shares of the company’s stock after buying an additional 3,099 shares during the quarter. Northern Trust Corp owned approximately 0.17% of Coya Therapeutics worth $164,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Newbridge Financial Services Group Inc. acquired a new position in Coya Therapeutics in the 4th quarter valued at $401,000. Tower Research Capital LLC TRC grew its stake in Coya Therapeutics by 1,005.7% in the 4th quarter. Tower Research Capital LLC TRC now owns 5,252 shares of the company’s stock valued at $30,000 after buying an additional 4,777 shares during the last quarter. Geode Capital Management LLC grew its stake in Coya Therapeutics by 5.8% in the 4th quarter. Geode Capital Management LLC now owns 150,576 shares of the company’s stock valued at $863,000 after buying an additional 8,267 shares during the last quarter. AIGH Capital Management LLC grew its stake in Coya Therapeutics by 85.0% in the 4th quarter. AIGH Capital Management LLC now owns 1,201,152 shares of the company’s stock valued at $6,883,000 after buying an additional 551,725 shares during the last quarter. Finally, CM Management LLC grew its stake in Coya Therapeutics by 11.1% in the 4th quarter. CM Management LLC now owns 160,000 shares of the company’s stock valued at $917,000 after buying an additional 15,941 shares during the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on COYA. D. Boral Capital reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a research note on Tuesday, April 22nd. Wall Street Zen lowered shares of Coya Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, May 22nd. Finally, Chardan Capital reissued a “buy” rating and issued a $14.00 price target on shares of Coya Therapeutics in a report on Tuesday, May 13th. One investment analyst has rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $17.00.

Coya Therapeutics Price Performance

Shares of Coya Therapeutics stock opened at $5.65 on Wednesday. Coya Therapeutics, Inc. has a fifty-two week low of $4.65 and a fifty-two week high of $10.24. The firm has a fifty day moving average price of $5.83 and a two-hundred day moving average price of $6.06. The company has a market cap of $94.50 million, a PE ratio of -8.69 and a beta of 0.49.

Coya Therapeutics (NASDAQ:COYA) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.44) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.44). The company had revenue of $257.88 million during the quarter, compared to the consensus estimate of $2.63 million. Analysts expect that Coya Therapeutics, Inc. will post -1.15 earnings per share for the current fiscal year.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc, a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy.